November 2022 - FMT, methotrexate and COVID vaccine boosters, and Palforzia for peanut allergy

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the November 2022 issue of DTB. They discuss the use of faecal microbiota transplantation to treat gastrointestinal infections and in particular its role in managing Clostridioides difficile infection (https://dtb.bmj.com/content/60/11/162). They highlight a study that assessed the effect of interrupting methotrexate treatment on COVID-19 booster vaccine response (https://dtb.bmj.com/content/60/11/163) and review a new drug that is licensed for treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy (https://dtb.bmj.com/content/60/11/166). The podcast begins with the editors talking about the response to October's editorial "Stop advertising". Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.